PriceTargets.com logo

Sio Gene Therapies - SIOX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.48 As of 02/8/2024 12:59 AM ET
▲ +0.008 (1.70%)
Get New Sio Gene Therapies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SIOX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SIOX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Sio Gene Therapies in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.48.

This chart shows the closing price for SIOX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Sio Gene Therapies. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/28/2022HC WainwrightDowngradeBuy ➝ SellHigh
4/28/2022Cantor FitzgeraldDowngradeOverweight ➝ Neutral$0.80High
2/1/2022HC WainwrightLower TargetBuy$10.00 ➝ $7.00High
2/1/2022SVB LeerinkDowngradeOutperform ➝ Market Perform$6.00 ➝ $1.00High
11/14/2021BTIG ResearchReiterated RatingBuy$8.00High
10/24/2021SVB LeerinkReiterated RatingBuyLow
10/19/2021HC WainwrightBoost TargetBuy ➝ Buy$8.00 ➝ $10.00Low
8/12/2021SVB LeerinkLower TargetOutperform$7.00 ➝ $6.00Medium
7/7/2021Chardan CapitalReiterated RatingBuyMedium
7/1/2021Chardan CapitalReiterated RatingBuyN/A
6/14/2021BTIG ResearchInitiated CoverageBuy$8.00High
6/13/2021Robert W. BairdReiterated RatingBuy$7.00Low
6/9/2021HC WainwrightReiterated RatingBuy$8.00High
5/5/2021Cantor FitzgeraldReiterated RatingOverweightHigh
4/30/2021HC WainwrightInitiated CoverageBuy$8.00Medium
12/16/2020SVB LeerinkBoost TargetOutperform$7.00 ➝ $8.00High
8/16/2020Chardan CapitalReiterated RatingBuy$12.50High
7/12/2020Cantor FitzgeraldReiterated RatingOverweight$11.00High
7/12/2020SVB LeerinkReiterated RatingOutperform$12.00High
7/12/2020GuggenheimReiterated RatingBuy ➝ Market Perform$23.00High
6/11/2020OppenheimerReiterated RatingHoldHigh
6/10/2020Chardan CapitalReiterated RatingBuy$15.00High
4/16/2020Cantor FitzgeraldInitiated CoverageOverweight$11.00High
4/9/2020Chardan CapitalReiterated RatingBuy$13.50High
10/28/2019Chardan CapitalBoost TargetBuy$10.00 ➝ $15.00Low
8/12/2019Robert W. BairdUpgradeNeutral ➝ Outperform$16.00 ➝ $13.00High
7/9/2019CowenReiterated RatingHoldHigh
6/21/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$18.00High
6/6/2019JMP SecuritiesBoost TargetOutperform$8.00 ➝ $28.00High
5/1/2019CowenReiterated RatingNeutral ➝ HoldLow
(Data available from 4/25/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Sio Gene Therapies logo
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
Read More

Today's Range

Now: $0.48
Low: $0.45
High: $0.48

50 Day Range

MA: $0.46
Low: $0.38
High: $0.48

52 Week Range

Now: $0.48
Low: $0.25
High: $0.50

Volume

40,400 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Sio Gene Therapies?

The following equities research analysts have issued reports on Sio Gene Therapies in the last twelve months:
View the latest analyst ratings for SIOX.

What is the current price target for Sio Gene Therapies?

0 Wall Street analysts have set twelve-month price targets for Sio Gene Therapies in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Sio Gene Therapies in the next year.
View the latest price targets for SIOX.

What is the current consensus analyst rating for Sio Gene Therapies?

Sio Gene Therapies currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SIOX.

What other companies compete with Sio Gene Therapies?

Other companies that are similar to Sio Gene Therapies include Context Therapeutics, Grifols, LAVA Therapeutics, Mainz Biomed and NLS Pharmaceutics. Learn More about companies similar to Sio Gene Therapies.

How do I contact Sio Gene Therapies' investor relations team?

Sio Gene Therapies' physical mailing address is 11 Times Square 33rd Floor New York, NY 10036. The company's listed phone number is (646) 677-6770 and its investor relations email address is [email protected]. The official website for Sio Gene Therapies is siogtx.com. Learn More about contacing Sio Gene Therapies investor relations.